Companies

Daiichi Sankyo to earn up to $7bn in AstraZeneca cancer drug deal

Japanese pharmaceutical receives testing and marketing muscle from global partner

Daiichi Sankyo AstraZeneca
March 29, 2019 13:37 JST

TOKYO -- Daiichi Sankyo has entered into an agreement with AstraZeneca to cooperate in clinical trials and commercialization of a new anti-cancer drug that Daiichi Sankyo is developing, the Japanese pharmaceutical announced on Friday.

Through the deal, AstraZeneca will pay Daiichi Sankyo up to $6.9 billion.

Read Next

Latest on Companies

  • Companies

    Kirin targets skin health in teamwork with subsidiary Fancl

    Kirin targets skin health in teamwork with subsidiary Fancl
  • Companies

    Lotte moves to shed struggling units in pivot toward growth areas

    Lotte moves to shed struggling units in pivot toward growth areas
  • Companies

    JT, rivals agree to $23bn to settle Canadian health risk lawsuits

    JT, rivals agree to $23bn to settle Canadian health risk lawsuits

    • Sponsored Content

    About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.